As showed in Table 4, a significant positive correlation was observed between LYRM4-AS1 and B cell’s biomarkers (CD19 and CD79A), CD4+ T cell’s biomarkers (CD4), M1 macrophage’s biomarkers (NOS2, IRF5, and PTGS2), M2 macrophage’s biomarkers (CD163, VSIG4, and MS4A4A), neutrophil’s biomarkers (CEACAM8, ITGAM and CCR7), T cell’s biomarkers (CD2, CD3E), Th1 cell’s biomarkers (TBX21, STAT4 and TNF), Th2 cell’s biomarkers (GATA3, STAT6, STAT5A and IL13) and Th17 cell’s biomarkers (STAT3 and IL17A) in glioma. This evidence concerns the gene CD79A and central nervous system cancer.